<?xml version="1.0" encoding="UTF-8"?>
<p>A: This is, of course, a core challenge, and efforts need to focus on mobilizing funds for priority pathogens such as the diseases on WHOâ€™s R&amp;D Blueprint list which currently includes COVID-19, MERS and SARS, among others. Dr Peter Hotez and his team collaborated with scientists at the University of Texas on a SARS vaccine, but they only got as far as animal trials due to a lack of funding.</p>
